Literature DB >> 34085289

Value-based drug pricing in the Biden era: Opportunities and prospects.

Peter J Neumann1, Daniel A Ollendorf1, Joshua T Cohen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34085289      PMCID： PMC8586482          DOI： 10.1111/1475-6773.13686

Source DB:  PubMed          Journal:  Health Serv Res        ISSN： 0017-9124            Impact factor:   3.734


× No keyword cloud information.
  43 in total

1.  Economic foundations of cost-effectiveness analysis.

Authors:  A M Garber; C E Phelps
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

Review 2.  Value-based insurance design.

Authors:  Michael E Chernew; Allison B Rosen; A Mark Fendrick
Journal:  Health Aff (Millwood)       Date:  2007-01-30       Impact factor: 6.301

3.  Pharmaceutical pricing: a review of proposals to improve access and affordability of prescription drugs.

Authors:  Paula Tironi
Journal:  Ann Health Law       Date:  2010

4.  Design, implementation, and first-year outcomes of a value-based drug formulary.

Authors:  Sean D Sullivan; Kai Yeung; Carol Vogeler; Scott D Ramsey; Edward Wong; Chad O Murphy; Dan Danielson; David L Veenstra; Louis P Garrison; Wylie Burke; John B Watkins
Journal:  J Manag Care Spec Pharm       Date:  2015-04

5.  FTC Gives Generics Victory On "Pay for Delay": Reverse Payments Crimped, Patent Thickets Untouched.

Authors:  Stephen Barlas
Journal:  P T       Date:  2019-05

6.  Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Nancy L Keating
Journal:  JAMA       Date:  2019-05-28       Impact factor: 56.272

7.  QALYs in 2018-Advantages and Concerns.

Authors:  Peter J Neumann; Joshua T Cohen
Journal:  JAMA       Date:  2018-06-26       Impact factor: 56.272

8.  Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.

Authors:  Laura Catherine Edney; Hossein Haji Ali Afzali; Terence Chai Cheng; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

9.  HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status.

Authors:  Diego Rosselli; Camila Quirland-Lazo; Marcell Csanádi; Eva María Ruiz de Castilla; Nelly Cisneros González; Julio Valdés; Cesar Abicalaffe; William Garzón; Giovanny Leon; Zoltán Kaló
Journal:  Value Health Reg Issues       Date:  2017-05-15

10.  Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.

Authors:  Warren G Linley; Dyfrig A Hughes
Journal:  Health Econ       Date:  2012-09-07       Impact factor: 3.046
View more
  2 in total

1.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

2.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.